Contego Medical said it pulled in $5.6 million in a Series B round to advance its embolic protection technology for angioplasty balloon and stent-delivery catheters.
Cardiovascular
Welcome to MassDevice's Cardiovascular Hub, your resource for the latest news in cardiac implants, structural heart, heart valves, stents and more. Stay informed about the innovations and business news shaping the cardiovascular device industry.
🫀 Narrow your focus with these categories:
Cardiac Implants | Structural Heart | Pulsed-Field Ablation
Here are top cardiology features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ LVADs save lives: So why aren’t more available?
+ How Medtronic uses nitinol to improve the structure and effectiveness of heart devices
+ How Abbott designed the world’s first dual-chamber leadless pacemaker system
+ J&J used RWE for expanded indications — and you can, too
+ 7 cardiology startups you need to know
Latest Cardiology News
Tendyne mitral valve study launches in U.S.
Tendyne Holdings this month said its transcatheter mitral valve implant was implanted in the 1st U.S. patient as part of a global feasibility study.
TAVI: Edwards CEO says Sapien 3 could hit U.S. market this year
Sunshine Heart can resume trial after FDA OKs ‘minor’ changes
LVADs: Leviticus Cardio raises $1.5m for wireless power tech
CardiAQ Valve wins FDA nod for mitral valve trial
CardiAQ Valve Technologies today said it won a nod from the FDA for an early feasibility trial of its 2nd-generation transcatheter mitral valve implant.
TAVI: Direct Flow to put its valve up against Medtronic’s CoreValve
Infraredx withdraws $56m IPO
Infraredx last week officially withdrew the planned initial public offering it hoped would raise $56 million, citing "unfavorable market conditions."
FDA expands indication for On-X Life’s heart valve
Widowmaker: Stents as safe as open heart surgery in left main artery disease
Miracor expands in the U.K.
Austria’s Miracor Medical Systems is boosting its presence in the U.K. with a new sales office and 2 clinical trials of its heart attack-treatment device.